Participation Reinforces Cadrenal's Commitment to
Innovation, Education and Improved Patient Outcomes with
Anticoagulation Therapy
PONTE
VEDRA, Fla., Oct. 23,
2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc.
(Nasdaq: CVKD), a late-stage biopharmaceutical company developing
tecarfarin, a new vitamin K antagonist (VKA) designed to improve
anticoagulation for patients with implanted cardiac devices or rare
cardiovascular conditions, today announced its membership in the
Corporate Council of the Anticoagulation Forum (AC Forum).
The AC Forum is the largest professional organization of
anticoagulation specialists, committed to advancing the quality and
safety of chronic anticoagulation care globally. Through
participation in the Corporate Council, Cadrenal Therapeutics will
collaborate with the AC Forum as it works to identify and address
unmet clinical needs, share cutting-edge research, and promote
advocacy and educational initiatives for the organization's 15,000
healthcare professional members aimed at improving outcomes for
patients on anticoagulants.
"Our membership in the AC Forum's Corporate Council reflects our
shared commitment to transforming anticoagulation care," said
Quang X. Pham, Chief Executive
Officer of Cadrenal Therapeutics. "We look forward to partnering
with the AC Forum and contributing to programs that advance safer,
more effective care and inform about ongoing research and
anticoagulation best practice guidelines."
Darren Triller, PharmD, Director
of Strategic Initiatives at the Anticoagulation Forum, welcomed
Cadrenal Therapeutics to the Corporate Council, saying: "We are
excited to have Cadrenal Therapeutics join us in our mission to
improve the quality of care for patients receiving antithrombotic
therapies. We look forward to a productive partnership that will
help us address the challenges in the anticoagulation landscape
together."
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics is a late-stage biopharmaceutical company
developing tecarfarin, a new vitamin K antagonist (VKA) designed to
offer safer, superior chronic anticoagulation for patients with
implanted cardiac devices or rare cardiovascular conditions.
Tecarfarin is anticipated to result in fewer adverse events such as
strokes, heart attacks, bleeds and deaths than warfarin, the most
commonly used anticoagulant for these patients despite its
prevalent side effects, drug-to-drug interactions and frequent
dosing changes. Tecarfarin received an orphan drug designation for
advanced heart failure patients with implanted left ventricular
assist devices (LVADs) as well as both orphan drug and fast-track
status for end-stage kidney disease patients with atrial
fibrillation. Cadrenal is planning pivotal clinical trials and
pursuing clinical and commercial partnerships. The company's plans
also include studying tecarfarin in patients with mechanical heart
valves experiencing anticoagulation difficulties. Visit
www.cadrenal.com to learn more.
About the Anticoagulation Forum
The Anticoagulation Forum has led advancements in
thrombosis-related care for over three decades. With more than
15,000 members across 3,000 healthcare institutions, the AC Forum
is dedicated to enhancing the safety and quality of care for over 1
million patients annually. Through education, thought leadership,
and partnerships with industry leaders, the AC Forum shapes the
future of anticoagulation management to ensure the best outcomes
for patients.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-joins-corporate-council-of-anticoagulation-forum-302283944.html
SOURCE Cadrenal Therapeutics, Inc.
